Immunotherapy after trauma: Timing is essential

Current Opinion in Anaesthesiology

Volumn 24, Issue 2, 2011, Pages 219-223

  Groeneveld, Kathelijne M ^a   Leenen, Luke P H ^a   Koenderman, Leo ^a   Kesecioglu, Jozef ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

cytokines; immunomodulation; immunotherapy; sepsis shock; trauma

Indexed keywords

HYPERTONIC SOLUTION; INTERLEUKIN 1; STRESS HORMONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL PRACTICE; COMPLEMENT SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; INJURY; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; CLINICAL TRIALS AS TOPIC; COMPLEMENT SYSTEM PROTEINS; HUMANS; HYPERTONIC SOLUTIONS; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; SHOCK; TIME FACTORS; WOUNDS AND INJURIES;

EID: 79952990788     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32834401e0     Document Type: Article

References (46)

1. Dutton RP, Stansbury LG, Leone S, et al. Trauma mortality in mature trauma systems: are we doing better? An analysis of trauma mortality patterns, 1997-2008. J Trauma 2010;69:620-626.
2. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995;38:185-193.
3. Saltzherr TP, Visser A, Ponsen KJ, et al. Complications in multitrauma patients in a Dutch Level 1 Trauma Center. J Trauma 2010;69:1143-1146.
4. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992;101:1481-1483.
5. Levy MM, Fink MP, Marshall JC, et al. 2001SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256. (Pubitemid 36444440)
6. Lustenberger T, Turina M, Seifert B, et al. The severity of injury and the extend of hemorrhagic shock predict the incidence of infectious complications in trauma patients. Eur J Trauma Emerg Surg 2009;35:538-546.
7. Groeneveld AB, Beishuizen A, Appelmelk BJ, Girbes AR. Adjuvant therapies for sepsis and shock: which are more effective? Ned Tijdschr Geneeskd 2001;145:1718-1722. (Pubitemid 32844396)
8. Dewar D, Moore FA, Moore EE, Balogh Z. Postinjury multiple organ failure. Injury 2009;40:912-918.
9. Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbrere JS. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 1985;120:1109-1115. (Pubitemid 16229682)
10. Nuytinck HK, Offermans XJ, Kubat K, Goris JA. Whole-body inflammation in trauma patients. An autopsy study. Arch Surg 1988;123:151 9-1524.
11. Guirao X, Lowry SF. Biologic control of injury and inflammation: much more than too little or too late. World J Surg 1996;20:437-446. (Pubitemid 26138591)
12. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697-1702. (Pubitemid 26193621)
13. Gullo A, Berlot G. Ingredients of organ dysfunction or failure. World J Surg 1996;20:430-436. (Pubitemid 26138590)
14. Fischer E, Marano MA, Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992;89:1551-1557.
15. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430-1439.
16. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294-1303.
17. Colin G, Annane D. Corticosteroids and human recombinant activated protein C for septic shock. Clin Chest Med 2008;29:705-712.
18. Britt RC, Devine A, Swallen KC, et al. Corticosteroid use in the intensive care unit: at what cost? Arch Surg 2006;141:145-149. (Pubitemid 43276561)
19. Rady MY, Johnson DJ, Patel B, et al. Cortisol levels and corticosteroid administration fail to predict mortality in critical illness: the confounding effects of organ dysfunction and sex. Arch Surg 2005;140:661-668. (Pubitemid 41124003)
20. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008;8:776-787. This nice review highlights recent insights in the molecular mechanisms in orderto find potential therapeutic targets in the treatment of sepsis.
21. Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 2008;34:1980-1990. This meta-analysis determines the clinical impact of immunonutrition in critically ill patients according to the type of formula.
22. Heyland DK, Samis A. Does immunonutrition in patients with sepsis do more harm than good? Intensive Care Med 2003;29:669-671. (Pubitemid 36609555)
23. Kurmis R, Parker A, Greenwood J. The use of immunonutrition in burn injury care: where are we? J Burn Care Res 2010;31:677-691.
24. Tsukamoto T, Chanthaphavong RS, Pape HC. Current theories on the pathophysiology of multiple organ failure after trauma. Injury 2010;41:21-26. A review of literature discussing the changing theories on inflammatory complications after trauma.
25. Fisher CJ Jr, Zheng Y. Potential strategies for inflammatory mediator manipulation: retrospect and prospect. World J Surg 1996;20:447-453. (Pubitemid 26138592)
26. Spruijt NE, Visser T, Leenen LP. A systematic review of randomized controlled trials exploring the effect of immunomodulative interventions on infection, organ failure, and mortality in trauma patients. Crit Care 2010;14: R150. This systematic review evaluates all randomized controlled trials that investigate the effect of non-nutritional immunomodulatory interventions in trauma patients.
27. Sauaia A, Moore FA, Moore EE, et al. Multiple organ failure can be predicted as early as 12 h after injury. J Trauma 1998;45:291-301.
28. Faist E, Schinkel C, Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg 1996;20:454-459. (Pubitemid 26138593)
29. Pillay J, Ramakers BP, Kamp VM, et al. Functional heterogeneity and differential priming of circulating neutrophils in human experimental endotoxemia. J Leukoc Biol 2010;88:211-220.
30. Fry DE. Multiple organ dysfunction syndrome: past, present and future. Surg Infect 2000;1:155-161.
31. Moore FA, Sauaia A, Moore EE, et al. Postinjury multiple organ failure: a bimodal phenomenon. J Trauma 1996;40:501-510. (Pubitemid 126425001)
32. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996;125:680-687. (Pubitemid 126450605)
33. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009;101:36-47.
34. Dorresteijn MJ, Visser T, Cox LA, et al. C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia. Crit Care Med 2010;38:2139-2145.
35. Keel M, Trentz O. Pathophysiology of polytrauma. Injury 2005;36:691-709. (Pubitemid 40732303)
36. Visser T, Pillay J, Koenderman L, Leenen LP. Postinjury immune monitoring: can multiple organ failure be predicted? Curr Opin Crit Care 2008;14:666-672.
37. Hietbrink F, Koenderman L, Althuizen M, Leenen LP. Modulation of the innate immune response after trauma visualised by a change in functional PMN phenotype. Injury 2009;40:851-855.
38. Pillay J, Hietbrink F, Koenderman L, Leenen LP. The systemic inflammatory response induced by trauma is reflected by multiple phenotypes of blood neutrophils. Injury 2007;38:1365-1372. (Pubitemid 350192398)
39. Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov 2010;9:43-56.
40. Ward PA. The harmful role of c5a on innate immunity in sepsis. J Innate Immun 2010;2:439-445.
41. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458-462. (Pubitemid 30367422)
42. Crandall M, Shapiro MB, West MA. Does splenectomy protect against immune-mediated complications in blunt trauma patients? Mol Med 2009;15:263-267.
43. Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009;9:418-428.
44. Rhind SG, Crnko NT, Baker AJ, et al. Prehospital resuscitation with hypertonic saline-dextran modulates inflammatory, coagulation and endothelial activation marker profiles in severe traumatic brain injured patients. J Neuroinflammation 2010;7:5.
45. Ghannam S, Bouffi C, Djouad F, et al. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 2010;1:2.
46. Russell JA, Walley KR. Vasopressin and its immune effects in septic shock. J Innate Immun 2010;2:446-460.